Chemed (CHE)
(Delayed Data from NYSE)
$587.39 USD
+9.62 (1.67%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $587.22 -0.17 (-0.03%) 6:18 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$587.39 USD
+9.62 (1.67%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $587.22 -0.17 (-0.03%) 6:18 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Zacks News
Is Chemed (CHE) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Chemed (CHE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Buy These 5 Low Leverage Stocks to Keep Your Portfolio Secure
by Zacks Equity Research
Since existence of a debt-free company is rare, the real challenge for an investor is determining whether an organization???s debt level is sustainable.
Chemed (CHE) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Chemed (CHE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand
by Zacks Equity Research
It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.
Chemed (CHE) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 8.74% and 0.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemed's Roto-Rooter & VITAS Robust, Acuity Mix Shift Weak
by Zacks Equity Research
Chemed's (CHE) VITAS shows higher adoption via an expanded average daily census. Also, the Roto-Rooter's business grows on the back of strong core plumbing and drain cleaning service segments.
Here's Why Chemed (CHE) Should Remain in Your Portfolio Now
by Zacks Equity Research
Investors' trust in Chemed (CHE) continues to be high, banking on its sturdy segmental performance.
DGX vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. CHE: Which Stock Is the Better Value Option?
Chemed's VITAS Business Strong, Weak Acuity Mix Shifts a Woe
by Zacks Equity Research
Chemed's (CHE) VITAS registers an expanded average daily census.
Why Is Chemed (CHE) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DGX vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Q1 Earnings Miss Estimates, Revenues Grow Y/Y
by Zacks Equity Research
Despite several downsides, Chemed (CHE) witnesses solid revenue growth across key subsidiaries - VITAS and Roto-Rooter.
DGX vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. CHE: Which Stock Is the Better Value Option?
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed (CHE) is expected to benefit from the launch of its VITAS Healthcare Inpatient Hospice Unit.
Here's Why You Should Hold on to DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.
Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
These 5 Stocks Make Great Buys on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Why Is Chemed (CHE) Up 2.7% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemed (CHE) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks.com featured expert Kevin Matras highlights: Balchem, Methode Electronics, Chemed, Ubiquiti Networks and HEXO
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Balchem, Methode Electronics, Chemed, Ubiquiti Networks and HEXO
5 Stocks in Focus on New Analysts Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.
Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries.